Treatment of renal cell cancer with programmed cell death 1 blockade: How much is enough?
Mené sur 168 patients atteints d'un carcinome rénal métastatique, cet essai de phase II évalue, pour un sous-groupe de patients, l'efficacité, du point de vue de la réponse tumorale, et la toxicité du nivolumab administré après la première observation d'une progression de la tumeur
In this issue of JAMA Oncology, George and colleagues report a retrospective subset analysis of patients with advanced clear cell renal cancer (RCC) treated beyond first progression (PD) in the phase 2 randomized clinical trial evaluating 3 different nivolumab dose levels. In the original report, among 168 randomized/167 treated patients, the objective response rates were reported as 20%, 22%, and 20% for the 0.3-, 2.0-, and 10-mg/kg doses, respectively.